PortfoliosLab logoPortfoliosLab logo
NXTC vs. AUPH
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NXTC vs. AUPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NXTC achieves a -87.24% return, which is significantly lower than AUPH's 12.10% return.


NXTC

1D
3.43%
1M
-76.88%
YTD
-87.24%
6M
-85.75%
1Y
-67.91%
3Y*
-54.58%
5Y*
-55.04%
10Y*

AUPH

1D
2.00%
1M
17.48%
YTD
12.10%
6M
10.30%
1Y
128.35%
3Y*
24.66%
5Y*
4.37%
10Y*
21.27%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NXTC vs. AUPH - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
NXTC
NextCure, Inc.
-87.24%53.37%-32.37%-19.15%-76.50%-44.95%-80.65%262.25%
AUPH
Aurinia Pharmaceuticals Inc.
12.10%77.62%-0.11%108.10%-81.11%65.37%-31.74%224.16%

Correlation

The correlation between NXTC and AUPH is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (All Time)
Calculated using the full available price history since May 9, 2019

0.24

The correlation between NXTC and AUPH shifts across timeframes, from 0.13 (1 year) to 0.24 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NXTC:

$9.48M

AUPH:

$2.46B

EPS

NXTC:

-$15.85

AUPH:

$2.15

PB Ratio

NXTC:

0.35

AUPH:

4.34

Total Revenue (TTM)

NXTC:

$0.00

AUPH:

$298.30M

Gross Profit (TTM)

NXTC:

-$365.00K

AUPH:

$267.70M

EBITDA (TTM)

NXTC:

-$54.25M

AUPH:

$153.45M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NXTC vs. AUPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NXTC
NXTC Risk / Return Rank: 1414
Overall Rank
NXTC Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
NXTC Sortino Ratio Rank: 2020
Sortino Ratio Rank
NXTC Omega Ratio Rank: 2020
Omega Ratio Rank
NXTC Calmar Ratio Rank: 1313
Calmar Ratio Rank
NXTC Martin Ratio Rank: 00
Martin Ratio Rank

AUPH
AUPH Risk / Return Rank: 9494
Overall Rank
AUPH Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
AUPH Sortino Ratio Rank: 9191
Sortino Ratio Rank
AUPH Omega Ratio Rank: 9393
Omega Ratio Rank
AUPH Calmar Ratio Rank: 9696
Calmar Ratio Rank
AUPH Martin Ratio Rank: 9595
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NXTC vs. AUPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NXTCAUPHDifference
Sharpe ratioReturn per unit of total volatility

-3.40

Sortino ratioReturn per unit of downside risk

-3.77

Omega ratioGain probability vs. loss probability

0.93

1.48

-0.55

Calmar ratioReturn relative to maximum drawdown

-0.78

8.12

-8.89

Martin ratioReturn relative to average drawdown

-2.42

17.70

-20.12

NXTC vs. AUPH - Sharpe Ratio Comparison

The current NXTC Sharpe Ratio is -0.58, which is lower than the AUPH Sharpe Ratio of 2.82. The chart below compares the historical Sharpe Ratios of NXTC and AUPH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NXTC vs. AUPH - Drawdown Comparison

The maximum NXTC drawdown since its inception was -99.84%, which is greater than AUPH's maximum drawdown of -87.58%. Use the drawdown chart below to compare losses from any high point for NXTC and AUPH.


Loading charts...

Drawdown Indicators


NXTCAUPHDifference

Max Drawdown

Largest peak-to-trough decline

-99.84%

-87.58%

-12.26%

Max Drawdown (1Y)

Largest decline over 1 year

-87.74%

-15.91%

-71.83%

Max Drawdown (3Y)

Largest decline over 3 years

-94.14%

-60.80%

-33.34%

Max Drawdown (5Y)

Largest decline over 5 years

-98.40%

-87.58%

-10.82%

Max Drawdown (10Y)

Largest decline over 10 years

-87.58%

Current Drawdown

Current decline from peak

-99.84%

-45.95%

-53.89%

Average Drawdown

Average peak-to-trough decline

-86.66%

-49.21%

-37.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

28.04%

7.28%

+20.76%

Volatility

NXTC vs. AUPH - Volatility Comparison

NextCure, Inc. (NXTC) has a higher volatility of 67.35% compared to Aurinia Pharmaceuticals Inc. (AUPH) at 9.56%. This indicates that NXTC's price experiences larger fluctuations and is considered to be riskier than AUPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NXTCAUPHDifference

Volatility (1M)

Calculated over the trailing 1-month period

67.35%

9.56%

+57.79%

Volatility (6M)

Calculated over the trailing 6-month period

90.90%

24.75%

+66.15%

Volatility (1Y)

Calculated over the trailing 1-year period

116.55%

45.80%

+70.75%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

79.91%

67.52%

+12.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

125.75%

73.73%

+52.02%

Dividends

NXTC vs. AUPH - Dividend Comparison

Neither NXTC nor AUPH has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NXTC vs. AUPH - Financials Comparison

This section allows you to compare key financial metrics between NextCure, Inc. and Aurinia Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M202220232024202520260
77.71M
(NXTC) Total Revenue
(AUPH) Total Revenue
Values in USD except per share items

Frequently Asked Questions


NXTC and AUPH have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NXTC has higher volatility (67.35%) compared to AUPH (9.56%). In terms of maximum drawdown, NXTC dropped -99.84% vs AUPH's -87.58%.

AUPH currently has the higher Sharpe Ratio (2.82 vs -0.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NXTC and AUPH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer